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Abstract
Background: Cardiovascular diseases (CVD) are the world’s leading cause of death and their prevalence is rising.
Diabetes and hypertension, major risk factors for CVD, are highly prevalent among the urban poor in Africa, but
treatment options are often limited in such settings. This study reports on the results of an intervention for the
treatment of diabetes and hypertension for adult residents of two slums in Nairobi, Kenya.
Methods: After setting up two clinics in two slums in Nairobi, hypertension and/or diabetes patients were seen by
a clinician monthly. Socio-demographic characteristics and clinical data were collected over a 34-month period.
Records were analyzed for 726 patients who visited the clinics at least once to determine clinic attendance and
compliance patterns using survival analysis. We also examined changes in systolic blood pressure (SBP), diastolic
blood pressure (DBP) and random blood glucose (RBG) during the course of the program.
Results: There was poor compliance with clinic attendance as only 3.4 % of patients attended the clinics on a
regular (monthly) basis throughout the 34-month period. 75 % of hypertension patients were not compliant after
four visits and 27 % of patients had only one clinic visit. Significant reduction of mean SBP and DBP (150.4 mmHg
to 141.5 mmHg, P = .003, and 89.3 mmHg to 83.2 mmHg, P < .001) was seen for all patients that stayed in care for
at least one year.
Conclusions: Establishing a preventative care and treatment system in low resource settings for CVD is challenging
due to high dropout rates and non-compliance. Innovative strategies are needed to ensure that benefits of
treatment programs are sustained for long-term CVD risk reduction in poor urban populations.
Keywords: Hypertension, Diabetes, Treatment, Cardiovascular diseases, Community-based, Sub-Saharan Africa,
Kenya, Slum
Background
Hypertension is the leading risk factor for CVD, and its
prevalence is increasing worldwide, from over 25 % in 2000
to a projected 40 % in 2025 [1, 2]. In Kenya the mean sys-
tolic blood pressure has increased from 127 to 132 mmHg
between 1990 and 2008 [3]. Although awareness on hyper-
tension seems to be low among the Kenyan population and
other developing countries [1, 4–6], recent findings in
Nairobi suggest that when people are made aware of having
hypertension, they tend to seek care for it [1]. Also, im-
proved physical access to health facilities leads to higher
use of them [7] and has been reported as a contributor in
reducing the overall CVD risk [8]. An intervention pro-
gram that improves awareness for CVD risk factors and in-
creases access to healthcare might therefore reduce the
burden of CVD.
For diabetes, it is estimated that the global prevalence
will increase from 6.9 % in 2010 to 7.7 % in 2030 [9].
The majority of this increase will occur in LMICs and
the urban poor population is likely to be most affected
[10, 11]. A recent study among residents of two Nairobi
slums showed an age-adjusted prevalence of 5.5 % but
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with significant age differences. For instance, in women
over the age of 60 years, the prevalence was 15 % [12].
Another study carried out in a different slum in Nairobi
showed similar prevalences, compared to a prevalence of
2.2 % in rural areas [13]. Among patients with diabetes
in urban slum communities in Nairobi the odds for
hypertension were two fold, resulting in 45.5 % of pa-
tients with diabetes being hypertensive. Similarly, 13 %
of patients with hypertension in these communities also
had diabetes [9].
Urban settings in general have a higher risk of devel-
oping CVD, largely due to adoption of sedentary life-
styles, dietary changes and psychosocial stress [14–17].
UN-HABITAT reports that approximately 58 % of the
Kenyan urban population lived in slums or slum-like
conditions in 2008, characterized by poor living condi-
tions and psychosocial stress [18, 19]. Considering the
above and the fact that improved glycemic control and
lowering blood pressures to normal values, both achiev-
able via the use of antidiabetic and antihypertensive
medication and lifestyle changes, can prevent CVD in
the future [20], the African Population and Health Re-
search Center (APHRC) executed a project from March
2009 to May 2012. This project aimed to provide better
access to high quality hypertension and diabetes care
and management in two slum communities underserved
by public health facilities. The aim of this paper is to
investigate whether this project can lead to health
benefits for people in low resource settings, specific-
ally by mapping the compliance patterns exhibited by
the patients and the effect of clinic attendance on




The project operated in two outreach clinics in two
slums –Korogocho and Viwandani– in Nairobi. These
clinics had been established out of necessity during a
previous cross-sectional CVD risk factor assessment sur-
vey in both slums also implemented by APHRC. At the
time of implementing the survey, there were no clinics
attending to patients with hypertension and or diabetes
in either slum. Therefore the APHRC set up two clinics
within existing primary health care facilities in both
slums. Participants in the cross-sectional survey who
were found to have elevated blood pressure or elevated
glucose values, or participants currently on medication
for diabetes or hypertension, were referred to the clinics.
At the clinics, adults diagnosed with hypertension and
diabetes could obtain treatment and advice on self-
management techniques. Elevated blood glucose levels
were defined as; RBG ≥11.0 mmol/L [21]. Hypertension
was defined as; SBP ≥ 140 mmHg and/or DBP ≥
90 mmHg or currently on anti-hypertensive medication
[22]. The clinics also attended to walk-in patients who
had not been referred from the cross-sectional survey but
had elevated blood pressure or glucose levels as defined
above and met the rest of the inclusion criteria.
The project provided the two clinics with basic diag-
nostic equipment (digital blood pressure monitors, gluc-
ometers) and qualified health personnel (clinical officers
and nurses). The clinics were open on a fortnightly basis.
Patients were expected to attend the clinics at least once
every four weeks or sometimes bi-weekly depending on
the severity of their blood pressure or blood glucose
readings. Patients who reached normal values were also
advised to visit the clinic every four weeks. Each visit pa-
tients were seen by a physician and had their blood pres-
sure and glucose measurements reassessed. They
received lifestyle counseling, which included dietary and
exercise advice and explanations of the risk factors and
complications of the diseases. In addition, they received
medication based on simple management guidelines. For
a period of two years, until March 2011, receiving care
and treatment at the clinics was absolutely free. There-
after, a user fee was introduced. The fees for consult-
ation, tests and a four weeks’ supply of drugs ranged
from about 2$ for patients with hypertension to 6$ for
patients with diabetes requiring insulin.
Study design
This was a facility-based follow up study of patients en-
rolled in the two clinics. At the first visit, data collected
included socio-demographic characteristics, diagnosis,
anthropometry, blood pressure and fasting blood glu-
cose. Each patient received a date for a follow up visit.
At each subsequent visit, clinical measurements of
weight, blood pressure and random blood glucose were
taken and treatment was evaluated. These clinical data
were later captured in an Epi-Info database.
Blood pressure was measured with validated oscillo-
metric automated digital BP devices (OMRON Digital
Automatic BP Monitor) used by qualified nurses or
physicians [23]. Three measurements were taken on
the left arm with one minute intervals while patients
were seated and silent. Averages of the second and
third measurements were used for analysis. Treatment
of hypertension was defined as receiving prescribed
antihypertensive medication for high blood pressure.
Blood glucose was measured using glucometers
(Accu-Chek Active Blood Glucose Meter System).
Treatment of diabetes was defined as receiving pre-
scribed insulin or oral hypoglycemic medication.
Since patients were typically given appointments four
weeks after any visit, we defined compliance as attending
the clinic within four weeks after the patient’s last visit,
with patients being non-compliant when the timespan
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between two visits exceeded four weeks. We defined
drop out of patients as failure to attend consecutive
scheduled consultations from any point in time until the
end of the 34-month period.
Statistical analysis
The study participants were divided in three groups based
on diagnosis: hypertension patients, diabetes patients and
patients having both hypertension and diabetes. Descrip-
tive analyses were conducted and group means were com-
pared using unpaired two-tailed t tests, variance analysis
(ANOVA) and chi-square tests. We looked at group dif-
ferences in area of residence and sex. Bivariate analyses
were conducted for the change in blood pressure and fast-
ing blood glucose over time (6 and 12 months) using
paired two tailed t tests, for patients who were enrolled in
the project for these periods. Due to high levels of attri-
tion, it was not possible to conduct any meaningful ana-
lyses beyond 12 months of follow up.
Power analyses were conducted to see whether the
tests performed have an adequate power to detect statis-
tical significance. Survival analysis was performed to
evaluate when non-compliance in different groups oc-
curred, with time to non-compliance being the event an-
alyzed. In all analyses P < .05 was considered statistically
significant. All analyses were performed using STATA
13.0 (Stata corp.).
Ethical considerations
This study was approved by the Kenya Medical Re-
search Institute/National Ethical Review Committee




Out of 5190 people screened in the CVD risk factor sur-
vey, 1238 were referred to the clinics of whom 113
(9.1 %) attended the clinics at least once. The rest of the
participants (625 patients) attended the clinic without
referral from the survey, resulting in a study population
of 726 participants (see Fig. 1). At registration mean SBP
among participants was 151.1 ± 28.9 mmHg, mean DBP
was 89.2 ± 15.5 mmHg and mean RBG was 10.9 ±
7.2 mmol/L. The descriptive characteristics of the study
population are presented in Tables 1 and 2. Up to 74 %
(545 patients) of the participants were hypertensive.
Among those with hypertension, mean SBP was 156.0
± 28.9 mmHg while the mean DBP was 92.6 ±
15.9 mmHg. The overall prevalence of diabetes in this
population was 55 %. Among patients with diabetes,
55 % (224 out of 405 patients) were hypertensive and
among patients with hypertension 41 % (224 out of
545 patients) were diabetic.
Analysis by area of residence was performed since
patients from different areas, and thus with different
demographics, could participate. This showed that
among patients with hypertension, mean SBP and
DBP was highest in men from outside Korogocho and
Viwandani (163.8 ± 29.7 mmHg and 96.6 ± 14.5 mmHg).
Diabetic men from Viwandani had the highest mean RBGs
(21.1 mmol/L).
For 2 different baseline data sets (containing partici-
pants who were in the program 6 and 12 months re-
spectively) characteristics were also determined. In all
patient groups females were overrepresented, ranging
from 51.0 % of patients with hypertension who partic-
ipated for at least 12 months to 63.0 % of patients
with both diseases who participated for at least
12 months. Furthermore, in every patient group most
people came from Viwandani (ranging from 43.6–
71 % of participants), only for diabetics who were in
the program for 12 months Korogocho was overrepre-
sented (51.6 %).
Patterns of clinic attendance and compliance
Findings on the patterns of clinic attendance for the en-
tire study population over a 12-months period showed
that up to 30 % of patients attended the clinic only once
and 5 % of all patients attended only twice. Over a
12 month period, 3.4 % (25 patients) of all patients con-
sistently attended the clinics every four weeks for a year.
In this group, the incidence of having both hypertension
and diabetes was 68 %. The rest of the patients had a
more irregular pattern of clinic attendance. Conducting
meaningful analyses beyond a 12 month period was not
possible due to high dropout rates. The mean number of
visits patients had in a year was 4.8 ± 3.9. Patients with
hypertension only had 3.3 ± 3.3 visits in a year, those
with diabetes only had 5.5 ± 3.7 and those with both dis-
eases reached 6.5 ± 4.2 visits a year. When we divided
patients in groups matching the number of appoint-
ments they had had during their participation in the
program we found that patients who attended the clinics
up to four times already had significant reductions in
mean SBP (to 144 ± 28.5 mmHg P = .001) and in mean
DBP (to 85.3 ± 14.7 mmHg, P = .001), regardless of com-
pliance. Furthermore, we found that with increasing
numbers of appointments disease parameters lowered,
with patients who had 12 appointments reaching a mean
SBP of 141.5 ± 25.5 mmHg (P = .003), and a mean DBP
of 83.2 ± 13.7 mmHg (P < .001).
In patients with hypertension, diabetes and both dis-
eases, 75 % were non-compliant respectively after 4, 10
and 14 visits (HR 1.27, 95 % CI 1.17-1.39, P < 0.001).
Figure 2 represents this visually. The differences in com-
pliance between patients with hypertension and those
with diabetes disappeared after approximately 8 months.
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After 15 months of treatment virtually everyone in every
patient group had become non-compliant. Although men
seemed less compliant than women, the median number
of visits before patients became non-compliant was two
for both sexes (HR 1.12, P = 0.151, 95 % CI 0.96-1.29). We
investigated the effects of introducing a user fee as a pos-
sible distorting factor in the patterns of compliance and
did not find any trend breaks, meaning that it did not have
a significant effect on clinic attendance. Also, the average
inflow of patients remained constant at 4 % after introduc-
tion of the fee.
Changes in blood pressure and RBG
We found that within a subpopulation that committed
to at least 12 clinic visits, the mean SBP decreased from
150.4 ± 28.5 mmHg to 141.5 ± 25.5 mmHg (P = .003)
(Table 3). A decrease was also found for mean DBP in
this group: from 89.3 ± 16.4 mmHg to 83.2 ± 13.7 mmHg
(P = .001). For mean RBG no significant changes were
observed for this group.
Among patients with only hypertension we found
significant reductions of the systolic (from 160.7 ±
32.1 mmHg to 139.3 ± 27.4 mmHg, P = .003) and dia-
stolic blood pressure (from 96.9 ± 19.6 mmHg to 84.1
± 13.9 mmHg, P = .002) after one year of clinic at-
tendance. For patients with diabetes and those with
both diseases there were no significant reductions in
systolic blood pressure or RBG after 12 months of
clinic attendance. DBP lowered in patients with both
diseases from 87.3 ± 14.6 mmHg to 83.1 ± 12.7 mmHg
(P = 0.028) (Table 3). When we conducted the same
analysis for patients who were in the program for
6 months we found a decrease in SBP and DBP for
patients with hypertension (Table 3). For the other
patient groups, no significant alterations were found
after 6 months.
Fig. 1 Flow chart of patients who met the inclusion criteria for participation in this study
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Table 1 Demographic data in the study population at baseline
Demographics (n = 726)
All (n = 726) HT only (n = 321) DM only (n = 181) HT&DM (n = 224)
Sex:
Male 282 (38.8 %) 145 (45.2 %) 67 (37.0 %) 70 (31.3 %)
Female 444 (61.2 %) 176 (54.8 %) 114 (63.0 %) 154 (68.8 %)
Residence:
Korogocho 122 (16.5 %) 43 (35.2 %) 35 (28.7 %) 44 (36.1 %)
Viwandani 269 (36.4 %) 150 (55.8 %) 58 (21.6 %) 61 (22.7 %)
Other 56 (7.6 %) 14 (25 %) 14 (25 %) 28 (50 %)
Missing 291 (39.4 %) 114 (35.5 %) 74 (40.9 %) 91 (40.6 %)
Referred:
Yes 113 (15.3 %) 44 (13.7 %) 41 (22.7 %) 28 (12.5 %)
No 625 (84.7 %) 277 (86.3 %) 140 (77.3 %) 196 (87.5 %)
HT only, diagnosed with hypertension only; DM only, diagnosed with diabetes only; HT&DM, diagnosed with hypertension and diabetes
Table 2 Disease parameters in the study population at baseline
Prevalence and disease parameters
Prevalence Population Male Female P value* M. vs. F.
Hypertension 74.9 % 76.2 % 74 % 0.495
Diabetes 55.6 % 48.6 % 60.1 % 0.002
Disease parameters
All (n = 726)
Mean ± SD Male ± SD Female ± SD P value** (95 % CI) M. vs. F.
SBP (mmHg) 151.1 ± 28.9 153.4 ± 27.1 149.7 ± 29.9 0.109 (148.9-154.3)
DBP (mmHg) 89.2 ± 15.5 89.3 ± 15.2 89.2 ± 15.7 0.922 (88.0-90.4)
RBG (mmol/L) 10.9 ± 7.2 11.5 ± 7.3 10.6 ± 7.1 0.332 (10.1-11.8)
Hypertension only (n = 321)
Mean ± SD Male ± SD Female ± SD P value**(95 % CI) M. vs. F.
SBP (mmHg) 156.0 ± 28.9 159.7 ± 27.1 152.8 ± 30.0 0.036 (152.7-159.2)
DBP (mmHg) 92.6 ± 15.9 92.9 ± 15.1 92.4 ± 16.7 0.772 (90.8-94.4)
RBG (mmol/L) 6.3 ± 3.7 6.9 ± 3.3 6.0 ± 3.8 0.401 (5.4-7.2)
Diabetes only (n = 181)
Mean ± SD Male ± SD Female ± SD P value** (95 % CI) M. vs. F.
SBP (mmHg) 139 ± 26.8 135.2 ± 21.9 141.0 ± 28.9 0.209 (134.7-143.2)
DBP (mmHg) 84.8 ± 14.6 81.8 ± 11.9 86.3 ± 15.6 0.066 (82.4-87.1)
RBG (mmol/L) 12.8 ± 8.6 14.7 ± 9.2 11.7 ± 8.0 0.111 (11.1-14.6)
Hypertension and diabetes (n = 224)
Mean ± SD Male ± SD Female ± SD P value** (95 % CI) M. vs. F.
SBP (mmHg) 152.7 ± 27.8 154.0 ± 24.7 152.1 ± 29.2 0.646 (148.8-156.6)
DBP (mmHg) 87.3 ± 14.2 87.4 ± 15.2 87.3 ± 13.8 0.961 (85.3-89.3)
RBG (mmol/L) 11.8 ± 6.5 11.1 ± 5.8 12.2 ± 6.8 0.346 (10.7-12.9)
SBP systolic blood pressure, DBP diastolic blood pressure, RBG random blood glucose. HT only, diagnosed with hypertension only; DM only, diagnosed with
diabetes only; HT&DM, diagnosed with hypertension and diabetes; SD, standard deviation; 95 % CI, 95 % confidence interval
*P values were calculated using Chi-Square tests
**P values were calculated using unpaired two-tailed T-test
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This led to hypertension control rates for SBP at base-
line, after 6 months and after 12 months of treatment of
31 %, 63 % and 32 % respectively. For DBP control rates
lowered from 50 % at baseline to 46 % after 6 months
and 38 % after 12 months of treatment. In this study,
the treatment effects for men and women in all patient
groups were similar.
When stratifying for area of residence it appeared that
the mean SBP and DBP in Korogocho and Viwandani
significantly decreased after one year. RBG was raised in
every location.
Discussion
The aim of this study was to investigate the effect of pri-
mary health care clinics, set up to treat hypertension
and diabetes in two Nairobi slums, on clinic attendance
patterns and clinical parameters among the attendees.
Key findings are that while there was an overall reduc-
tion in mean blood pressure for patients that were still
in the project after 12 months, compliance with care
was very poor.
In recent years it has become clear that prevention
programs for CVD in low- and middle income countries
are cost-effective [20] and scalable when targeting im-
portant risk factors [24, 25]. Several succesful interven-
tions have been implemented in low-income settings to
tackle the increasing burden of non-communicable dis-
eases, specifically CVD [26, 27]. However, a study which
evaluated the attendance of an intervention similar to
the one in this study, carried out in Dar es Salaam in
2008 suggests low use of health care services and poor
treatment compliance after 12 months [28]. In this case,
treatment costs and lack of symptoms were reasons re-
ported for not attending care.
In our study population it was remarkable that al-
though people were referred to the clinics from a mass
screening campaign, only a small fraction of them
attended the clinic (113 out of 1238), and the majority
of patients attended on their own accord without refer-
ral. This shows that there are still challenges to over-
come in order to successfully implement a screen-and-
treat intervention approach in low-resource settings. It
is not clear why such a small fraction of referred patients
showed up at the clinic even though they were aware
that the cost of care was initially free. A separate study
by APHRC in Korogocho slum [29] which involved
door-to-door screening for hypertension found that the
reasons given for non-attendance to clinics after referral
include lack of time or money, forgetfulness, and lack of
understanding of health benefits of attendance (APHRC,
unpublished data). The large proportion of un-referred
patients attending the clinics points to a large unmet
need for care among patients already diagnosed and per-
haps more aware of the benefits of treatment. This could
also point to barriers to affordability of treatment. Treat-
ment costs for hypertension or diabetes outside the
slums could be as high as 10 to 20 times the user fee
that was introduced at both clinics.
From the patterns of attendance we observed that only
a small percentage of participants in this study visited
the clinics consistently over the 12-month follow up
period. These patterns also show high dropout rates, in
particular after the first visit (27 %) of which the vast
majority were patients with hypertension (67 %).
Fig. 2 Survival analysis of compliance by the different diagnosed groups. The y-axis shows the fraction of patients by diagnosis, the x-axis shows
the compliance over time in weeks. The blue line indicates patients with both diseases, the red line indicates patients with diabetes and the
green line indicates patients with hypertension
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Survival analysis demonstrates that patients with hyper-
tension are the least compliant. Possible reasons for high
dropout rates and low compliance of patients with
hypertension might be the lack of symptoms in hyper-
tension, low awareness and a low priority for treatment
[28]. These findings are consistent with earlier studies,
which state that drop-out rates in low-income settings
are often high, in particular when no symptoms are re-
ported or when treatment costs are substantial [28, 30].
However, the introduction of the user fee in this study
did not affect clinic attendance. This finding is partly at-
tributable to the fact that the majority of patients had
already dropped out and no new patients had been re-
cruited in the six months prior to the introduction of the
fees. Another possible contributor to the high dropout
rates might have been that when blood pressure or blood
glucose was controlled or improving, people considered
themselves cured and stopped attending the clinics. In our
study population we found that patients who attended the
clinics for longer periods of time had higher mean blood
pressures at baseline, implying that patients with lower
blood pressures might drop out early, and possibly, that
patients who have blood pressures more resistant to treat-
ment stay in the program longer.
We observed that in the entire study population, al-
though dropout rates were very high, the systolic and
diastolic blood pressure had significantly lowered after
12 months. However, this population comprised patients
with both regular and irregular attendance patterns. Pa-
tients who had had more visits showed more significant
decreases, making it plausible that the impact on disease
parameters increases when patients attend the clinics
more often. A possible explanation for this finding is
that people who attend more regularly are more likely to
also take their medication more regularly and are likely
to be more stimulated to commit to lifestyle changes.
The program seemed to have had positive effects for
people with hypertension: after one year of clinic attend-
ance there were significant reductions in mean SBP and
DBP. One possible explanation for this is that when pa-
tients receive treatment, the rate of control of hyperten-
sion can rise to nearly 40 % [31]. However, when
looking at control rates for hypertension, it seemed
that although we found a steep increase for the con-
trol rate of SBP after 6 months of treatment, control
rates reached baseline values again after 12 months of
treatment. The fact that these effects disappeared
later, emphasizes the difficulties of long-term disease
management in these settings.
A quite consistent finding in this study is the gradual
rise of RBG over time. This might be due to low compli-
ance rates in the study population and possibly to low
compliance to medication intake, which was not mea-
sured in this study. It also reflects the fact that such dis-
eases may require intensive disease management, which
could be quite challenging in low-resource settings.















All patients (n = 237) (n = 154)
SBP (mmHg) ± SD 148.5 ± 28.3 139.4 ± 25.4 (Δ -9.1) <0.001 (141.5-146.4) 150.4 ± 30.3 141.5 ± 25.5 (Δ -8.9) 0.003 (142.7-149.1)
DBP (mmHg) ± SD 88.0 ± 15.4 82.9 ± 15.3 (Δ -5.1) 0.002 (84.0-86.8) 89.3 ± 16.4 83.2 ± 13.7 (Δ -6.1) <0.001 (84.5-87.9)
RBG (mmol/L) ± SD 11.3 ± 6.7 11.3 ± 8.8 (Δ -0.0) 0.5308 (10.5-12.1) 10.7 ± 6.1 11.8 ± 6.8 (Δ +1.1) 0.909 (10.4-12.1)
Hypertension only (n = 65) (n = 33)
SBP (mmHg) ± SD 158.2 ± 26.0 136.2 ± 25.9 (Δ -22.0) <0.001 (142.5-152.2) 160.7 ± 32.1 139.3 ± 27.4 (Δ -21.4) 0.003 (142.5-158.1)
DBP (mmHg) ± SD 94.8 ± 15.1 82.9 ± 15.4 (Δ -11.9) <0.001 (86.1-91.7) 96.9 ± 19.6 84.1 ± 13.9 (Δ -12.8) 0.002 (86.2-95.1)
RBG (mmol/L) ± SD 6.5 ± 3.3 7.1 ± 4.5 (Δ +0.6) 0.738 (5.7-7.8) 8.4 ± 5.2 10.5 ± 6.9 (Δ +2.1) 0.789 (6.8-11.9)
Diabetes only (n = 69) (n = 40)
SBP (mmHg) ± SD 139.9 ± 30.6 136.0 ± 20.6 (Δ -3.9) 0.192 (133.6-142.4) 140.1 ± 33.7 132.5 ± 23.9 (Δ -7.6) 0.132 (129.6-142.9)
DBP (mmHg) ± SD 85.5 ± 15.1 82.9 ± 16.6 (Δ -2.6) 0.171 (81.5-86.9) 87.8 ± 15.7 82.5 ± 13.1 (Δ -5.3) 0.058 (81-7-88.4)
RBG (mmol/L) ± SD 12.6 ± 7.7 11.5 ± 6.4 (Δ -1.1) 0.203 (10.7-13.3) 10.2 ± 6.5 11.5 ± 7.3 (Δ +1.3) 0.774 (9.2-12.6)
Hypertension & diabetes (n = 100) (n = 80)
SBP (mmHg) ± SD 147.7 ± 26.7 143.9 ± 27.8 (Δ -3.8) 0.161 (142.0-149.6) 152.3 ± 26.7 146.7 ± 25.1 (Δ -5.6) 0.092 (145.3-153.6)
DBP (mmHg) ± SD 85.2 ± 14.6 83.4 ± 14.2 (Δ -1.8) 0.180 (82.3-86.3) 87.3 ± 14.6 83.1 ± 12.7 (Δ -4.2) 0.028 (83.0-87.4)
RBG (mmol/L) ± SD 11.9 ± 6.2 12.1 ± 10.6 (Δ +0.2) 0.558 (10.7-13.3) 11.6 ± 6.1 12.4 ± 6.8 (Δ +0.8) 0.750 (10.9-13.1)
SBP systolic blood pressure, DBP diastolic blood pressure, RBG random blood glucose SD standard deviation, Δ difference between baseline means and means
after 6 or 12 months, 95 % CI 95 % confidence interval
*P value calculated with paired two-tailed T-test after 6 and 12 months in comparison with the corresponding baseline value
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There were some limitations to this study. Given
the important reduction in the number of patients
returning for follow-up visits, we had to work with
small populations in certain analyses. This drastically
limits the external validity of our findings on the ef-
fects on blood parameters. Also, we used RBG as a
disease parameter which is not an accurate measure
because of high inter- and intrapersonal fluctuations.
HbA1c tests, which are more reliable in determining
glycemic control over time, were available, but not
free and the majority of patients decided not to get
tested. Therefore, analyzing HbA1c was not possible
in the study population. RBG is used as a starting
point for referral because its low cost and quick de-
termination of blood glucose values make it an easy-
to-use method for glucose measurement in the field.
Conclusions
This study demonstrates that establishing a preventative
care and treatment system in low resource settings for
CVD is challenging due to high dropout rates and non-
compliance. To address this problem, it is important to
raise awareness of treatment compliance in slums since
non-communicable diseases such as CVD often need
lifelong treatment. The study also demonstrated that a
screen-and-treat based approach for referral and treat-
ment was not very effective in this poor population.
Overall, there is urgent need for more research in in-
novative approaches to improve patient compliance in
these challenging settings.
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